Showing 621-640 of 644 for: Cochrane Systematic Reviews > Psychiatric and substance abuse 
- Valerian for anxiety disorders
Cochrane Systematic Reviews, 5-Nov-2008
Anxiety disorders are very common mental health problems in the general population and in primary care settings. Herbal medicines are popular and used worldwide and might be considered as a treatment option for anxiety if shown to be effective and safe.
- Validation therapy for dementia
Cochrane Systematic Reviews, 21-Jul-2003
Validation therapy was developed by Naomi Feil between 1963 and 1980 for older people with cognitive impairments. Initially, this did not include those with organically-based dementia, but the approach has subsequently been applied in work with people who
- Valproate for acute mania
Cochrane Systematic Reviews, 7-Oct-2019
Bipolar disorder is a severe and common mental disorder where patients experience recurrent symptoms of elevated or irritable mood, depression, or a combination of both. Treatment is usually with psychiatric medication, including mood stabilisers, antidep
- Valproate for schizophrenia
Cochrane Systematic Reviews, 24-Nov-2016
Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, and valproate is one of these.
- Valproate preparations for agitation in dementia
Cochrane Systematic Reviews, 5-Oct-2018
Agitation has been reported in up to 90% of people with dementia. Agitation in people with dementia worsens carer burden, increases the risk of injury, and adds to the need for institutionalisation. Valproate preparations have been used in an attempt to c
- Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder
Cochrane Systematic Reviews, 16-Oct-2013
Bipolar disorder is a recurrent illness that is amongst the top 30 causes of disability worldwide and is associated with significant healthcare costs. In the past, emphasis was placed solely on the treatment of acute episodes of bipolar disorder; recently
- Velnacrine for Alzheimer's disease
Cochrane Systematic Reviews, 12-May-2008
Alzheimer's disease (AD) is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts of
- Vinpocetine for cognitive impairment and dementia
Cochrane Systematic Reviews, 20-Jan-2003
Vinpocetine is a synthetic ethyl ester of apovincamine, a vinca alkaloid obtained from the leaves of the Lesser Periwinkle (Vinca minor) and discovered in the late 1960s. Although used in human treatment for over twenty years, it has not been approved by
- Visual feedback of individuals' medical imaging results for changing health behaviour
Cochrane Systematic Reviews, 20-Jan-2010
Feedback of medical imaging results can reveal visual evidence of actual bodily harm attributable to a given behaviour. This may offer a particularly promising approach to motivating changes in health behaviour to decrease risk. Applicable behaviours incl
- Vitamin B12 for cognition
Cochrane Systematic Reviews, 21-Jul-2003
An association between neuropsychiatric disorders and vitamin B12 deficiency has been recognized since 1849 when pernicious anaemia was first described. It has been suggested that deficiency of vitamin B12 might contribute to age-associated cognitive impa
- Vitamin B6 for cognition
Cochrane Systematic Reviews, 12-May-2008
Micronutrient status can affect cognitive function at all ages. Vitamin deficiencies could influence memory function and might contribute to age-associated cognitive impairment and dementia. Vitamin B6, comprising three chemically distinct compounds, pyri
- Vitamin E for Alzheimer's dementia and mild cognitive impairment
Cochrane Systematic Reviews, 18-Apr-2017
Vitamin E occurs naturally in the diet. It has several biological activities, including functioning as an antioxidant to scavenge toxic free radicals. Evidence that free radicals may contribute to the pathological processes behind cognitive impairment has
- Vitamin E for antipsychotic‐induced tardive dyskinesia
Cochrane Systematic Reviews, 17-Jan-2018
Antipsychotic (neuroleptic) medication is used extensively to treat people with chronic mental illnesses. Its use, however, is associated with adverse effects, including movement disorders such as tardive dyskinesia (TD) – a problem often seen as repetiti
- Vocational rehabilitation for people with severe mental illness
Cochrane Systematic Reviews, 23-Apr-2001
Unemployment rates are high amongst people with severe mental illness, yet surveys show that most want to work. Vocational rehabilitation services exist to help mentally ill people find work. Traditionally, these services have offered a period of preparat
- Workplace interventions for smoking cessation
Cochrane Systematic Reviews, 26-Feb-2014
The workplace has potential as a setting through which large groups of people can be reached to encourage smoking cessation.
- Yizhi capsule for vascular dementia
Cochrane Systematic Reviews, 18-Apr-2007
Vascular dementia (VD) is a syndrome or diagnosis that has different causes and clinical manifestations relating to several different vascular mechanisms and changes in the brain. Some traditional Chinese herbal medicines were developed for treating VD. Y
- Zhiling decoction for vascular dementia
Cochrane Systematic Reviews, 5-May-2008
Zhiling decoction has a fixed composition of 15 Chinese herbs. The properties of each of these herbs and in combination provide the therapeutic rationale for a possible action of Zhiling decoction in dilating cerebral vessels and increasing cerebral blood
- Ziprasidone for schizophrenia and severe mental illness
Cochrane Systematic Reviews, 18-Jan-2012
Typical antipsychotic drugs are widely used as the first line treatment for people with schizophrenia. However, the atypical class of antipsychotic drugs are making important inroads into this approach. Atypical is a widely used term used to describe some
- Ziprasidone versus other atypical antipsychotics for schizophrenia
Cochrane Systematic Reviews, 7-Oct-2009
In many countries of the industrialised world second generation ('atypical') antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various new generation
- Zotepine for schizophrenia
Cochrane Systematic Reviews, 18-Oct-2006
Zotepine is a relatively new antipsychotic often used for the treatment of people with schizophrenia. It is claimed to be particularly effective for negative symptoms.
